Market Cap 1.22B
Revenue (ttm) 407.32M
Net Income (ttm) -61.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15.12%
Debt to Equity Ratio 1.37
Volume 2,918,500
Avg Vol 3,562,196
Day's Range N/A - N/A
Shares Out 247.03M
Stochastic %K 30%
Beta 0.61
Analysts Strong Sell
Price Target $16.30

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 745 1700
Address:
400 Fifth Avenue, Suite 210, Waltham, United States
BrexitIsStupid
BrexitIsStupid Aug. 4 at 12:43 PM
$ARDX Back in the 4's, FFS The game is rigged, always has been, always will be.
0 · Reply
TwinTurboBul161
TwinTurboBul161 Aug. 4 at 9:50 AM
0 · Reply
Krambo88
Krambo88 Aug. 4 at 9:44 AM
$ARDX Operating expenses are the key metric I’m watching this quarter with ARDX. Strong revenue growth is great, but operating costs need to be under control for sustained profitability. My expectations unfortunately are low.
0 · Reply
Cameohitch
Cameohitch Aug. 4 at 9:42 AM
$ARDX "We're proud to share that Gut Matters: Discoveries & Innovations, Ardelyx's podcast, has been named a finalist in the #FiercePharmaMarketingAwards in the Podcast or Audio category. This recognition reflects our commitment to creating educational content that elevates important conversations in GI health and brings together experts to explore the latest perspectives shaping patient care. Thank you to everyone who helps bring Gut Matters Podcast to life. We're honored to be recognized alongside so many outstanding organizations and look forward to celebrating with our fellow finalists!" https://www.linkedin.com/posts/johannahruddy_ibs-ibs-ardelyxproud-activity-7490127299187748864-NEPt https://www.fiercepharmaweek.com/fiercepharmaweekcom/2026-finalists
0 · Reply
findingthestock
findingthestock Aug. 4 at 1:33 AM
$ARDX $7.11 is very high avg and to watch it go down.. sucks
0 · Reply
Biocontrol
Biocontrol Aug. 3 at 7:13 PM
$ARDX I sold some covered calls today as a hedge, so that way we can be sure Thursday is a blowout.
3 · Reply
8BALLIAM
8BALLIAM Aug. 3 at 6:53 PM
$ARDX 1600 aug 5 puts went up
0 · Reply
janed102
janed102 Aug. 3 at 6:24 PM
$ARDX understand your frustration
0 · Reply
TonyStar
TonyStar Aug. 3 at 5:27 PM
$ARDX doing a nice all time high at google trends
0 · Reply
knowinvest
knowinvest Aug. 3 at 5:08 PM
$ARDX can blame xbi for today lol
0 · Reply
Latest News on ARDX
Ardelyx assumed with a Buy at Ladenburg

2026-06-16T11:57:58.000Z - 7 weeks ago

Ardelyx assumed with a Buy at Ladenburg


Ardelyx Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 9:55 AM EDT - 2 months ago

Ardelyx Transcript: Jefferies Global Healthcare Conference 2026


Ardelyx Proxy statement: Proxy filing

May 26, 2026, 8:00 AM EDT - 2 months ago

Ardelyx Proxy statement: Proxy filing


Ardelyx Proxy statement: Proxy filing

May 19, 2026, 8:00 AM EDT - 2 months ago

Ardelyx Proxy statement: Proxy filing


Ardelyx reports Q1 EPS (15c), consensus (14c)

2026-04-30T21:07:15.000Z - 3 months ago

Ardelyx reports Q1 EPS (15c), consensus (14c)


Ardelyx Earnings Call Transcript: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

Ardelyx Earnings Call Transcript: Q1 2026


Ardelyx Earnings release: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

Ardelyx Earnings release: Q1 2026


Ardelyx Quarterly report: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

Ardelyx Quarterly report: Q1 2026


Ardelyx Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Ardelyx Proxy statement: Proxy filing


Ardelyx appoints Ettenberg as Chief Legal Officer

2026-04-20T12:50:41.000Z - 3 months ago

Ardelyx appoints Ettenberg as Chief Legal Officer


Ardelyx appoints Rajani Dinavahi as chief medical officer

2026-04-01T12:17:42.000Z - 4 months ago

Ardelyx appoints Rajani Dinavahi as chief medical officer


Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Apr 1, 2026, 8:01 AM EDT - 4 months ago

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx


Ardelyx Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 4:20 PM EDT - 5 months ago

Ardelyx Transcript: Leerink Global Healthcare Conference 2026


Zevra Therapeutics appoints Renz as Chief Financial Officer

2026-03-05T13:09:46.000Z - 5 months ago

Zevra Therapeutics appoints Renz as Chief Financial Officer

ZVRA


Ardelyx to Participate in Upcoming Investor Conferences

Mar 4, 2026, 8:00 AM EST - 5 months ago

Ardelyx to Participate in Upcoming Investor Conferences


Ardelyx, LPGA announce multi-year partnership

2026-02-24T13:18:35.000Z - 5 months ago

Ardelyx, LPGA announce multi-year partnership


Ardelyx price target raised to $18 from $10 at H.C. Wainwright

2026-02-20T11:12:08.000Z - 5 months ago

Ardelyx price target raised to $18 from $10 at H.C. Wainwright


Ardelyx reports Q4 EPS 0c, consensus 1c

2026-02-19T22:00:37.000Z - 5 months ago

Ardelyx reports Q4 EPS 0c, consensus 1c


Ardelyx Earnings Call Transcript: Q4 2025

Feb 19, 2026, 4:30 PM EST - 5 months ago

Ardelyx Earnings Call Transcript: Q4 2025


Ardelyx Earnings release: Q4 2025

Feb 19, 2026, 4:30 PM EST - 5 months ago

Ardelyx Earnings release: Q4 2025


Ardelyx Annual report: Q4 2025

Feb 19, 2026, 4:30 PM EST - 5 months ago

Ardelyx Annual report: Q4 2025


Ardelyx Slides: Q4 2025

Feb 19, 2026, 4:30 PM EST - 5 months ago

Ardelyx Slides: Q4 2025


Ardelyx receives new patent for Tenapanor

2026-02-03T13:41:00.000Z - 6 months ago

Ardelyx receives new patent for Tenapanor


Ardelyx Receives New Patent for Tenapanor

Feb 3, 2026, 8:29 AM EST - 6 months ago

Ardelyx Receives New Patent for Tenapanor


Ardelyx price target raised to $13 from $10 at TD Cowen

2026-01-29T14:35:34.000Z - 6 months ago

Ardelyx price target raised to $13 from $10 at TD Cowen


Ardelyx announces first patient dosed in ACCEL

2026-01-28T13:38:18.000Z - 6 months ago

Ardelyx announces first patient dosed in ACCEL


Ardelyx price target raised to $15 from $8 at Jefferies

2026-01-27T11:25:47.000Z - 6 months ago

Ardelyx price target raised to $15 from $8 at Jefferies


Ardelyx price target raised to $14 from $11 at Citi

2026-01-09T12:45:43.000Z - 7 months ago

Ardelyx price target raised to $14 from $11 at Citi


Ardelyx price target raised to $17 from $14 at BTIG

2026-01-09T11:00:13.000Z - 7 months ago

Ardelyx price target raised to $17 from $14 at BTIG


Ardelyx upgraded to Overweight from Neutral at Piper Sandler

2026-01-08T21:35:56.000Z - 7 months ago

Ardelyx upgraded to Overweight from Neutral at Piper Sandler


Ardelyx Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 11:30 AM EST - 9 months ago

Ardelyx Transcript: Jefferies London Healthcare Conference 2025


Ardelyx Transcript: Wedbush Rewind ASN 2025 Conference

Nov 10, 2025, 11:30 AM EST - 9 months ago

Ardelyx Transcript: Wedbush Rewind ASN 2025 Conference


Ardelyx Earnings Call Transcript: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 9 months ago

Ardelyx Earnings Call Transcript: Q3 2025


Ardelyx Quarterly report: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 9 months ago

Ardelyx Quarterly report: Q3 2025


Ardelyx Earnings release: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 9 months ago

Ardelyx Earnings release: Q3 2025


Ardelyx Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 8:35 AM EDT - 11 months ago

Ardelyx Transcript: Cantor Global Healthcare Conference 2025


Ardelyx Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 1:00 PM EDT - 11 months ago

Ardelyx Transcript: Citi's Biopharma Back to School Conference


Ardelyx Earnings Call Transcript: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings Call Transcript: Q2 2025


Ardelyx Quarterly report: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Quarterly report: Q2 2025


Ardelyx Earnings release: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings release: Q2 2025


Ardelyx Announces Changes to the Executive Leadership Team

Aug 4, 2025, 4:08 PM EDT - 1 year ago

Ardelyx Announces Changes to the Executive Leadership Team


Ardelyx Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings Call Transcript: Q1 2025


Ardelyx Quarterly report: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Quarterly report: Q1 2025


Ardelyx Earnings release: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings release: Q1 2025


Ardelyx Slides: Corporate Presentation

Apr 30, 2025, 6:00 PM EDT - 1 year ago

Ardelyx Slides: Corporate Presentation


Ardelyx Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Ardelyx Proxy statement: Proxy Filing


Ardelyx Transcript: Leerink Global Healthcare Conference 2025

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Ardelyx Transcript: Leerink Global Healthcare Conference 2025


Tenapanor Approved in China for Hyperphosphatemia

Feb 26, 2025, 7:00 AM EST - 1 year ago

Tenapanor Approved in China for Hyperphosphatemia


BrexitIsStupid
BrexitIsStupid Aug. 4 at 12:43 PM
$ARDX Back in the 4's, FFS The game is rigged, always has been, always will be.
0 · Reply
TwinTurboBul161
TwinTurboBul161 Aug. 4 at 9:50 AM
0 · Reply
Krambo88
Krambo88 Aug. 4 at 9:44 AM
$ARDX Operating expenses are the key metric I’m watching this quarter with ARDX. Strong revenue growth is great, but operating costs need to be under control for sustained profitability. My expectations unfortunately are low.
0 · Reply
Cameohitch
Cameohitch Aug. 4 at 9:42 AM
$ARDX "We're proud to share that Gut Matters: Discoveries & Innovations, Ardelyx's podcast, has been named a finalist in the #FiercePharmaMarketingAwards in the Podcast or Audio category. This recognition reflects our commitment to creating educational content that elevates important conversations in GI health and brings together experts to explore the latest perspectives shaping patient care. Thank you to everyone who helps bring Gut Matters Podcast to life. We're honored to be recognized alongside so many outstanding organizations and look forward to celebrating with our fellow finalists!" https://www.linkedin.com/posts/johannahruddy_ibs-ibs-ardelyxproud-activity-7490127299187748864-NEPt https://www.fiercepharmaweek.com/fiercepharmaweekcom/2026-finalists
0 · Reply
findingthestock
findingthestock Aug. 4 at 1:33 AM
$ARDX $7.11 is very high avg and to watch it go down.. sucks
0 · Reply
Biocontrol
Biocontrol Aug. 3 at 7:13 PM
$ARDX I sold some covered calls today as a hedge, so that way we can be sure Thursday is a blowout.
3 · Reply
8BALLIAM
8BALLIAM Aug. 3 at 6:53 PM
$ARDX 1600 aug 5 puts went up
0 · Reply
janed102
janed102 Aug. 3 at 6:24 PM
$ARDX understand your frustration
0 · Reply
TonyStar
TonyStar Aug. 3 at 5:27 PM
$ARDX doing a nice all time high at google trends
0 · Reply
knowinvest
knowinvest Aug. 3 at 5:08 PM
$ARDX can blame xbi for today lol
0 · Reply
Autolus_Freakk
Autolus_Freakk Aug. 3 at 4:48 PM
$ARDX even my AUTL stock is doing better than this shit.. that says a lot...
2 · Reply
Abundance11
Abundance11 Aug. 3 at 4:10 PM
$ARDX will never get out of my 7.11 average. This ceo is one of the worst ive ever seen. Does ZERO for shareholder value. Just uses the company like an ATM, issues shsres, sell shares, repeat. Hoping hes fired but that wont happen because he gives the board their shares too. One of the only Bios ive seen actually making 500 million a year and trading like a company in preclinical stages. Absolute
8 · Reply
TragicRain
TragicRain Aug. 3 at 3:50 PM
$ARDX - full transparency - I have bought and sold my lots 2x already - Bought in the $5's and sold in the $9's.... My current CB is $5.03 - I beleive this will pop to $9 again....
0 · Reply
TragicRain
TragicRain Aug. 3 at 3:44 PM
$ARDX - What I like (2) commercial products IBSRELA is growing rapidly and XPHOZAH provides a second revenue stream. Strong revenue growth Q1 2026 product revenue was $93.4 million, up 38% year over year. Management reaffirmed 2026 guidance of: IBSRELA: $410–430M XPHOZAH: $110–120M Sorry I am silly like that - those are sexy numbers - this will pop again. I will continue to buy under $6
1 · Reply
jbh973
jbh973 Aug. 3 at 3:41 PM
Thanks to the local drunk guy passed out on a bench outside the 7-11, a winning $10 lottery scratch off, 78 cents, & a bottle cap found its way into my hands. So it's with a giant size Slurpee & 2 artery clogging patties containing some form of ''meat'', I give u... THE MIDDAY STOCK MARKET REVIEW ( The There's more than 1 way to describe ''Convenience'' store Edition ) $LKNCY If u told me 10 yrs ago I would 1 day use the phrase ''King of Chinese coffee'' in a sentence I would of called u nuts. $NGEN I estimate in another 4-6 weeks this ticker is going to make me look really good. This could go to $112.83 based solely on my theory that money always seems to find its way to the truly joyless, of which this room is filled with. $ARDX Further research has concluded this has something to do with discarded chicken bones but too many smart ones in this so I'm sticking to chicken. $MOB If it goes back to $6 I'm flipping again. $VZ Stealthily finding it's way back to $50. 😀
1 · Reply
Cameohitch
Cameohitch Aug. 3 at 10:58 AM
$ARDX Tenapanor is referenced in a new Italian paper: "How are developments in the treatment armamentarium of hyperphosphatemia addressing the current therapeutic challenges?" "Recent developments in hyperphosphatemia management have increasingly focused on non–binder-based inhibition of intestinal phosphate absorption, with tenapanor representing the most clinically relevant innovation.." https://www.tandfonline.com/doi/full/10.1080/14656566.2026.2688300#d1e218
0 · Reply
opportoni
opportoni Aug. 3 at 8:45 AM
$ARDX From Kyowa Kirin Report:
7 · Reply
OldManLogan
OldManLogan Aug. 3 at 2:58 AM
$ARDX $NGEN $LRMR $OCGN Don't let Adam Furenstein or anyone else convince you that a Bristol Myers/ Astrazeneca merger isn't bullish for the broader biotech space... if it goes through, other mids and big boys will accelerate their scale up and if it fails due to antitrust or shareholder revolt, both BMS and AZN will pivot to a cheaper by the dozen approach...
2 · Reply
findingthestock
findingthestock Aug. 2 at 9:24 PM
$ARDX when is Raab going to sell the company, find a buyer Shareholders have stuck behind the company for years
2 · Reply
Cjs2027
Cjs2027 Aug. 2 at 8:57 PM
$ARDX The possible indications to be explored for 531 are mind boggling.
0 · Reply
TheYoungGeologist
TheYoungGeologist Aug. 2 at 7:29 PM
$ARDX wonder if we get a market headwind or tailwind for earnings
0 · Reply
crypto_biotech
crypto_biotech Aug. 2 at 12:51 PM
0 · Reply